Medpace (NASDAQ:MEDP) Now Covered by Analysts at Leerink Partners

Leerink Partners assumed coverage on shares of Medpace (NASDAQ:MEDP) in a research note issued to investors on Monday, MarketBeat.com reports. The brokerage issued a market perform rating and a $330.00 price target on the stock.

Separately, Robert W. Baird raised their price target on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Eight investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $376.30.

Medpace Price Performance

NASDAQ:MEDP opened at $330.59 on Monday. Medpace has a one year low of $302.01 and a one year high of $459.77. The company has a market cap of $10.07 billion, a PE ratio of 26.17, a PEG ratio of 3.81 and a beta of 1.47. The firm has a 50-day moving average of $337.29 and a 200-day moving average of $339.65.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, equities research analysts expect that Medpace will post 12.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Medpace

Several institutional investors and hedge funds have recently bought and sold shares of MEDP. Wealth Enhancement Advisory Services LLC increased its holdings in Medpace by 245.6% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 8,371 shares of the company’s stock worth $2,781,000 after acquiring an additional 5,949 shares during the last quarter. Armis Advisers LLC bought a new stake in Medpace during the 4th quarter valued at $278,000. Ascent Group LLC boosted its holdings in shares of Medpace by 16.8% in the fourth quarter. Ascent Group LLC now owns 9,374 shares of the company’s stock worth $3,114,000 after acquiring an additional 1,349 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of Medpace in the fourth quarter valued at $217,000. Finally, Palisades Investment Partners LLC raised its stake in shares of Medpace by 9.2% during the 4th quarter. Palisades Investment Partners LLC now owns 15,919 shares of the company’s stock valued at $5,289,000 after purchasing an additional 1,338 shares during the period. 77.98% of the stock is owned by institutional investors.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.